Related Experiment Video
Updated: Jul 16, 2026
08:02
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Lactoferrin-Derived Peptides in Cancer Therapy: Structural Features, Mechanistic Insights and Clinical Translation
Abdulkadir Cidem1,2, Chih-Ching Yen1,3, Ke-Rong Chen1
1Department of Life Sciences, and Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan.
International Journal of Molecular Sciences
|July 15, 2026
Summary
Lactoferrin-derived peptides (LDPs) show promise as anticancer agents by targeting cancer cells. This review explores LDP structures, mechanisms, and their potential for cancer therapy development.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Lactoferrin-derived peptides (LDPs) are cationic fragments from lactoferrin.
- Key LDPs include lactoferricin (LFcin) and lactoferrampin (LFampin).
- Engineered LDPs offer enhanced anticancer properties.
Purpose of the Study:
- To review LDP classes and their anticancer potential.
- To elucidate structure-activity relationships for LDPs.
- To discuss challenges and opportunities in LDP cancer therapeutics.
Main Methods:
- Review of existing literature on LDPs.
- Analysis of structural modifications and their impact.
- Examination of LDP mechanisms against cancer cells.
Main Results:
- LDPs exhibit preferential binding to malignant cells.
- Structural features dictate membrane interaction and selectivity.
- LDPs induce tumor suppression via apoptosis and immune modulation.
Conclusions:
- LDPs represent a promising class of anticancer peptides.
- Understanding LDP structure-activity relationships is crucial for therapeutic development.
- Further research is needed to translate LDPs into clinical cancer treatments.
